X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
PRO 140 (leronlimab) is a CCR5 antagonist with the potential for multiple therapeutic indications. It is being evaluated for the treatment of HIV infection.
Lead Product(s): Leronlimab
Therapeutic Area: Infections and Infectious Diseases Product Name: PRO 140
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 29, 2024
Details:
PRO 140 (leronlimab) is a CCR5 antagonist with the potential for multiple therapeutic indications. It is being evaluated in phase 2 clinical trials for the treatment of HIV infection.
Lead Product(s): Leronlimab
Therapeutic Area: Infections and Infectious Diseases Product Name: PRO 140
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 01, 2024
Details:
PRO 140 (leronlimab) is an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes.
Lead Product(s): Leronlimab
Therapeutic Area: Infections and Infectious Diseases Product Name: PRO 140
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 28, 2022
Details:
The grant will fund the development and preclinical research of a single-injection gene therapy that codes for the leronlimab protein sequence and which will be delivered via an adeno-associated virus (AAV) vector.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Oregon Health & Science University
Deal Size: $5.0 million Upfront Cash: Undisclosed
Deal Type: Funding July 11, 2022
Details:
Leronlimab treatment reduced SHIV viral loads by 10,000 fold and leronlimab was found within all anatomical compartments analyzed, including mucosal and lymphatic tissues, sites of early viral replication after transmission and latency.
Lead Product(s): Leronlimab
Therapeutic Area: Infections and Infectious Diseases Product Name: PRO 140
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 12, 2022
Details:
Leronlimab, an investigational humanized IgG4 monoclonal antibody (mAb) that is designed to bind to C-C chemokine receptor type 5 (CCR5), a protein on the surface of certain immune system cells that is believed to play a role in numerous disease processes.
Lead Product(s): Leronlimab
Therapeutic Area: Infections and Infectious Diseases Product Name: PRO 140
Highest Development Status: Phase II/ Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 30, 2022
Details:
The trial was conducted in two parts for PRO 140 (Leronlimab), Part 1 compared a 700 mg weekly dose and Part 2 evaluated a 350 mg weekly dose, positive result is obtained from the 350 mg weekly dose for Phase 2 NASH clinical trial.
Lead Product(s): Leronlimab
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: PRO 140
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 05, 2022
Details:
During recent discussions with the FDA, the agency suggested that developing Vyrologix (leronlimab) for critically ill COVID-19 patients in current situation in U.S. appears feasible.
Lead Product(s): Leronlimab
Therapeutic Area: Infections and Infectious Diseases Product Name: Vyrologix
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2021
Details:
Phase 3 pivotal trial yielded a statistically significant primary endpoint for efficacy (p=0.0032), had an 81% success rate in suppressing viral load (VL<50 cp/mL) in the MDR population after 24 weeks of Vyrologix (leronlimab) treatment.
Lead Product(s): Leronlimab
Therapeutic Area: Infections and Infectious Diseases Product Name: Vyrologix
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 09, 2021
Details:
Company developing Vyrologix (leronlimab), a CCR5 antagonist announced that its CRO in Brazil met with ANVISA to modify the CD16 trial for critically ill COVID-19 patients.
Lead Product(s): Leronlimab
Therapeutic Area: Infections and Infectious Diseases Product Name: Vyrologix
Highest Development Status: Phase IIIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 08, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
